The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Lymphoma, T-Cell, Cutaneous

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Lymphoma, T-Cell, Cutaneous


High impact information on Lymphoma, T-Cell, Cutaneous


Chemical compound and disease context of Lymphoma, T-Cell, Cutaneous


Biological context of Lymphoma, T-Cell, Cutaneous


Anatomical context of Lymphoma, T-Cell, Cutaneous


Gene context of Lymphoma, T-Cell, Cutaneous


Analytical, diagnostic and therapeutic context of Lymphoma, T-Cell, Cutaneous


  1. Hodgkin's disease, lymphomatoid papulosis, and cutaneous T-cell lymphoma derived from a common T-cell clone. Davis, T.H., Morton, C.C., Miller-Cassman, R., Balk, S.P., Kadin, M.E. N. Engl. J. Med. (1992) [Pubmed]
  2. Treatment of cutaneous T-cell lymphoma (mycosis fungoides) with 13-cis-retinoic acid. Kessler, J.F., Meyskens, F.L., Levine, N., Lynch, P.J., Jones, S.E. Lancet (1983) [Pubmed]
  3. Oltipraz, an inhibitor of human immunodeficiency virus type 1 replication. Prochaska, H.J., Yeh, Y., Baron, P., Polsky, B. Proc. Natl. Acad. Sci. U.S.A. (1993) [Pubmed]
  4. Impaired CD40L signaling is a cause of defective IL-12 and TNF-alpha production in Sézary syndrome: circumvention by hexameric soluble CD40L. French, L.E., Huard, B., Wysocka, M., Shane, R., Contassot, E., Arrighi, J.F., Piguet, V., Calderara, S., Rook, A.H. Blood (2005) [Pubmed]
  5. CD30-CD30 ligand interaction in primary cutaneous CD30(+) T-cell lymphomas: A clue to the pathophysiology of clinical regression. Mori, M., Manuelli, C., Pimpinelli, N., Mavilia, C., Maggi, E., Santucci, M., Bianchi, B., Cappugi, P., Giannotti, B., Kadin, M.E. Blood (1999) [Pubmed]
  6. Treatment of cutaneous T-cell lymphoma with beta carotene. Baranowitz, S.A. N. Engl. J. Med. (1994) [Pubmed]
  7. Interleukin-7 is a growth factor for Sézary lymphoma cells. Dalloul, A., Laroche, L., Bagot, M., Mossalayi, M.D., Fourcade, C., Thacker, D.J., Hogge, D.E., Merle-Béral, H., Debré, P., Schmitt, C. J. Clin. Invest. (1992) [Pubmed]
  8. Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy. Carrera, C.J., Terai, C., Lotz, M., Curd, J.G., Piro, L.D., Beutler, E., Carson, D.A. J. Clin. Invest. (1990) [Pubmed]
  9. Cutaneous T-cell lymphoma and calcitriol and isotretinoin treatment. Thomsen, K. Lancet (1995) [Pubmed]
  10. Treatment of cutaneous T-cell lymphoma by retinoids and calcitriol. French, L.E., Saurat, J.H. Lancet (1995) [Pubmed]
  11. Remission of cutaneous T-cell lymphoma with combined calcitriol and acitretin. French, L.E., Ramelet, A.A., Saurat, J.H. Lancet (1994) [Pubmed]
  12. Isotretinoin in cutaneous T-cell lymphoma. Warrell, R.P., Coonley, C.J., Kempin, S.J., Myskowski, P., Safai, B., Itri, L.M. Lancet (1983) [Pubmed]
  13. A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Foss, F., Demierre, M.F., DiVenuti, G. Blood (2005) [Pubmed]
  14. An investigation of 2'-deoxycoformycin in the treatment of cutaneous T-cell lymphoma. Grever, M.R., Bisaccia, E., Scarborough, D.A., Metz, E.N., Neidhart, J.A. Blood (1983) [Pubmed]
  15. Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma. Kuzel, T.M., Hurria, A., Samuelson, E., Tallman, M.S., Roenigk, H.H., Rademaker, A.W., Rosen, S.T. Blood (1996) [Pubmed]
  16. Interleukin-7 and interleukin-15 regulate the expression of the bcl-2 and c-myb genes in cutaneous T-cell lymphoma cells. Qin, J.Z., Zhang, C.L., Kamarashev, J., Dummer, R., Burg, G., Döbbeling, U. Blood (2001) [Pubmed]
  17. Inducible expression of MS-1 high-molecular-weight protein by endothelial cells of continuous origin and by dendritic cells/macrophages in vivo and in vitro. Goerdt, S., Bhardwaj, R., Sorg, C. Am. J. Pathol. (1993) [Pubmed]
  18. Arsenic trioxide induces apoptosis of cutaneous T cell lymphoma cells: evidence for a partially caspase-independent pathway and potentiation by ascorbic acid (vitamin C). Michel, L., Dupuy, A., Jean-Louis, F., Sors, A., Poupon, J., Viguier, M., Musette, P., Dubertret, L., Degos, L., Dombret, H., Bachelez, H. J. Invest. Dermatol. (2003) [Pubmed]
  19. CD4 + /CD7- T cell frequency and polymerase chain reaction-based clonality assay correlate with stage in cutaneous T cell lymphomas. Laetsch, B., Häffner, A.C., Döbbeling, U., Seifert, B., Ludwig, E., Burg, G., Dummer, R. J. Invest. Dermatol. (2000) [Pubmed]
  20. Molecular cytogenetic detection of chromosomal breakpoints in T-cell receptor gene loci. Gesk, S., Martín-Subero, J.I., Harder, L., Luhmann, B., Schlegelberger, B., Calasanz, M.J., Grote, W., Siebert, R. Leukemia (2003) [Pubmed]
  21. T-cell lines established from human T-lymphocytic neoplasias by direct response to T-cell growth factor. Poiesz, B.J., Ruscetti, F.W., Mier, J.W., Woods, A.M., Gallo, R.C. Proc. Natl. Acad. Sci. U.S.A. (1980) [Pubmed]
  22. Functional characterization of neurotensin receptors in human cutaneous T cell lymphoma malignant lymphocytes. Ramez, M., Bagot, M., Nikolova, M., Boumsell, L., Vita, N., Chalon, P., Caput, D., Ferrara, P., Bensussan, A. J. Invest. Dermatol. (2001) [Pubmed]
  23. Soluble interleukin-2 receptors inhibit interleukin 2-dependent proliferation and cytotoxicity: explanation for diminished natural killer cell activity in cutaneous T-cell lymphomas in vivo? Dummer, R., Posseckert, G., Nestle, F., Witzgall, R., Burger, M., Becker, J.C., Schäfer, E., Wiede, J., Sebald, W., Burg, G. J. Invest. Dermatol. (1992) [Pubmed]
  24. Synergistic enhancement of cell-mediated immunity by interleukin-12 plus interleukin-2: basis for therapy of cutaneous T cell lymphoma. Zaki, M.H., Wysocka, M., Everetts, S.E., Wang, K.S., French, L.E., Ritz, J., Rook, A.H. J. Invest. Dermatol. (2002) [Pubmed]
  25. Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma. Vowels, B.R., Lessin, S.R., Cassin, M., Jaworsky, C., Benoit, B., Wolfe, J.T., Rook, A.H. J. Invest. Dermatol. (1994) [Pubmed]
  26. Interleukin-15 is an autocrine/paracrine viability factor for cutaneous T-cell lymphoma cells. Döbbeling, U., Dummer, R., Laine, E., Potoczna, N., Qin, J.Z., Burg, G. Blood (1998) [Pubmed]
  27. Interferon-alpha resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression. Sun, W.H., Pabon, C., Alsayed, Y., Huang, P.P., Jandeska, S., Uddin, S., Platanias, L.C., Rosen, S.T. Blood (1998) [Pubmed]
  28. Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas. Mao, X., Orchard, G., Lillington, D.M., Russell-Jones, R., Young, B.D., Whittaker, S.J. Blood (2003) [Pubmed]
  29. Functional expression of the eotaxin receptor CCR3 in CD30+ cutaneous T-cell lymphoma. Kleinhans, M., Tun-Kyi, A., Gilliet, M., Kadin, M.E., Dummer, R., Burg, G., Nestle, F.O. Blood (2003) [Pubmed]
  30. Costimulation of cutaneous T-cell lymphoma cells by interleukin-7 and interleukin-2: potential autocrine or paracrine effectors in the Sézary syndrome. Foss, F.M., Koc, Y., Stetler-Stevenson, M.A., Nguyen, D.T., O'Brien, M.C., Turner, R., Sausville, E.A. J. Clin. Oncol. (1994) [Pubmed]
  31. Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. Toro, J.R., Liewehr, D.J., Pabby, N., Sorbara, L., Raffeld, M., Steinberg, S.M., Jaffe, E.S. Blood (2003) [Pubmed]
  32. Radioimmunotherapy of patients with cutaneous T-cell lymphoma using an iodine-131-labeled monoclonal antibody: analysis of retreatment following plasmapheresis. Zimmer, A.M., Rosen, S.T., Spies, S.M., Goldman-Leikin, R., Kazikiewicz, J.M., Silverstein, E.A., Kaplan, E.H. J. Nucl. Med. (1988) [Pubmed]
  33. cTAGE: a cutaneous T cell lymphoma associated antigen family with tumor-specific splicing. Usener, D., Schadendorf, D., Koch, J., Dübel, S., Eichmüller, S. J. Invest. Dermatol. (2003) [Pubmed]
  34. The hypoxic cytotoxin SR 4233 increases the effectiveness of radioimmunotherapy in mice with human non-Hodgkin's lymphoma xenografts. Wilder, R.B., McGann, J.K., Sutherland, W.R., Waller, E.K., Minchinton, A.I., Goris, M.L., Knox, S.J. Int. J. Radiat. Oncol. Biol. Phys. (1994) [Pubmed]
WikiGenes - Universities